Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Nov;24(5):599–606. doi: 10.1111/j.1365-2125.1987.tb03218.x

Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.

R Donnelly 1, H L Elliott 1, P A Meredith 1, J L Reid 1
PMCID: PMC1386331  PMID: 3325090

Abstract

1. In nine patients with essential hypertension, following single and multiple doses of ketanserin, assessments were made of blood pressure and heart rate, QT interval, and pressor responses to phenylephrine and angiotensin II. 2. Significant reductions in blood pressure occurred for 6 h after the first dose, on average 23/14 mm Hg supine, and there was a comparable antihypertensive effect after 1 month's treatment. 3. There were small but significant rightward shifts (1.5 to 2-fold) in the phenylephrine pressor-response curves but no changes in the responsiveness to angiotensin II. 4. The QT interval (QTc) was significantly increased after 1 month's treatment: at 1 h after dosing 334 +/- 32 ms after 1 month of ketanserin compared with 302 +/- 31 ms after placebo. 5. The elimination half-life and AUC for ketanserin were both significantly increased at steady state compared with the first dose: respectively 13.4 vs 4.3 h for half-life and 830 vs 437 ng ml-1 h for AUC. 6. Ketanserin had no significant effects on baroreflex function, plasma renin activity, aldosterone, catecholamines and 24 h urinary excretion.

Full text

PDF
599

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. De Crée J., Leempoels J., Geukens H., De Cock W., Verhaegen H. The antihypertensive effects of ketanserin (R 41468), a novel 5-hydroxytryptamine-blocking agent, in patients with essential hypertension. Clin Sci (Lond) 1981 Dec;61 (Suppl 7):473s–476s. doi: 10.1042/cs061473s. [DOI] [PubMed] [Google Scholar]
  2. Derkx F. H., Bouma B. N., Tan-Tjiong H. L., Man in 't Veld A. J., de Bruyn J. H., Wenting G. J., Schalekamp M. A. Role of plasma kallikrein in the proteolytic activation of the renin-angiotensin system. Clin Exp Hypertens. 1980;2(3-4):575–592. doi: 10.3109/10641968009037131. [DOI] [PubMed] [Google Scholar]
  3. Fagard R., Fiocchi R., Lijnen P., Staessen J., Amery A. Hemodynamic response to chronic ketanserin treatment in essential hypertension. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S128–S129. doi: 10.1097/00005344-198500077-00038. [DOI] [PubMed] [Google Scholar]
  4. Fagard R., Fiocchi R., Lijnen P., Staessen J., Moerman E., de Schaepdryver A., Amery A. Haemodynamic and humoral responses to chronic ketanserin treatment in essential hypertension. Br Heart J. 1984 Feb;51(2):149–156. doi: 10.1136/hrt.51.2.149. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Frenken M., Kaumann A. J. Interaction of ketanserin and its metabolite ketanserinol with 5HT2 receptors in pulmonary and coronary arteries of calf. Naunyn Schmiedebergs Arch Pharmacol. 1984 Jul;326(4):334–339. doi: 10.1007/BF00501438. [DOI] [PubMed] [Google Scholar]
  6. Hedner T., Persson B. Antihypertensive properties of ketanserin in combination with beta-adrenergic blocking agents. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S161–S163. doi: 10.1097/00005344-198500077-00045. [DOI] [PubMed] [Google Scholar]
  7. Hedner T., Pettersson A., Persson B. Blood pressure reduction and pharmacokinetics of ketanserin in hypertensive patients. J Hypertens Suppl. 1986 Apr;4(1):S91–S93. [PubMed] [Google Scholar]
  8. Kuhn D. M., Wolf W. A., Lovenberg W. Review of the role of the central serotonergic neuronal system in blood pressure regulation. Hypertension. 1980 May-Jun;2(3):243–255. doi: 10.1161/01.hyp.2.3.243. [DOI] [PubMed] [Google Scholar]
  9. Kurowski M. Bioavailability and pharmacokinetics of ketanserin in elderly subjects. Eur J Clin Pharmacol. 1985;28(4):411–417. doi: 10.1007/BF00544359. [DOI] [PubMed] [Google Scholar]
  10. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  11. McKenzie J. K., Clements J. A. Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity. J Clin Endocrinol Metab. 1974 Apr;38(4):622–627. doi: 10.1210/jcem-38-4-622. [DOI] [PubMed] [Google Scholar]
  12. Okonkwo P. O., Reimann I. W., Woestenborghs R., Klotz U. High-performance liquid chromatographic assay with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2 antagonist in human plasma, blood and urine. J Chromatogr. 1983 Feb 11;272(2):411–416. doi: 10.1016/s0378-4347(00)86149-6. [DOI] [PubMed] [Google Scholar]
  13. Olanoff L. S., Cook J. A., Eller T., Knapp D. R., Halushka P. V. Protective effects of trans-13-APT, a thromboxane receptor antagonist, in endotoxemia. J Cardiovasc Pharmacol. 1985 Jan-Feb;7(1):114–120. doi: 10.1097/00005344-198501000-00019. [DOI] [PubMed] [Google Scholar]
  14. Omvik P., Lund-Johansen P. Long-term effects on central haemodynamics and body fluid volumes of ketanserin in essential hypertension studies at rest and during dynamic exercise. J Hypertens. 1983 Dec;1(4):405–412. doi: 10.1097/00004872-198312000-00014. [DOI] [PubMed] [Google Scholar]
  15. PAGE I. H., MCCUBBIN J. W. The variable arterial pressure response to serotonin in laboratory animals and man. Circ Res. 1953 Jul;1(4):354–362. doi: 10.1161/01.res.1.4.354. [DOI] [PubMed] [Google Scholar]
  16. Persson B., Hedner T., Berglund G. Ketanserin in essential hypertension: effects during rest and exercise. Eur J Clin Pharmacol. 1983;25(3):307–312. doi: 10.1007/BF01037939. [DOI] [PubMed] [Google Scholar]
  17. Persson B., Pettersson A., Hedner T. Pharmacokinetics of ketanserin in patients with essential hypertension. Eur J Clin Pharmacol. 1987;32(3):259–265. doi: 10.1007/BF00607573. [DOI] [PubMed] [Google Scholar]
  18. Reimann I. W., Frölich J. C. Mechanism of antihypertensive action of ketanserin in man. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):381–383. doi: 10.1136/bmj.287.6389.381-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Rocco S., Boscaro M., D'Agostino D., Armanini D., Opocher G., Mantero F. Effect of ketanserin on the in vitro regulation of aldosterone. J Hypertens Suppl. 1986 Apr;4(1):S51–S54. [PubMed] [Google Scholar]
  20. Soffer J., Dreifus L. S., Michelson E. L. Polymorphous ventricular tachycardia associated with normal and long Q-T intervals. Am J Cardiol. 1982 Jun;49(8):2021–2029. doi: 10.1016/0002-9149(82)90224-7. [DOI] [PubMed] [Google Scholar]
  21. Sumner D. J., Elliott H. L., Reid J. L. Analysis of the pressor dose response. Clin Pharmacol Ther. 1982 Oct;32(4):450–458. doi: 10.1038/clpt.1982.188. [DOI] [PubMed] [Google Scholar]
  22. Van Nueten J. M., Janssen P. A., De Ridder A., Vanhoutte P. M. Interaction between 5-hydroxytryptamine and other vasoconstrictor substances in the isolated femoral artery of the rabbit; effect of ketanserin (R 41 468). Eur J Pharmacol. 1982 Feb 5;77(4):281–287. doi: 10.1016/0014-2999(82)90130-3. [DOI] [PubMed] [Google Scholar]
  23. Van Nueten J. M., Janssen P. A., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther. 1981 Jul;218(1):217–230. [PubMed] [Google Scholar]
  24. Van Peer A., Woestenborghs R., Embrechts L., Heykants J. Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Eur J Clin Pharmacol. 1986;31(3):339–342. doi: 10.1007/BF00981134. [DOI] [PubMed] [Google Scholar]
  25. Yee Y. G., Rubin P. C., Meffin P. Prazosin determination by high-pressure liquid chromatography using fluorescence detection. J Chromatogr. 1979 Apr 21;172:313–318. doi: 10.1016/s0021-9673(00)90967-1. [DOI] [PubMed] [Google Scholar]
  26. Zabludowski J. R., Ball S. G., Robertson J. I. Ketanserin and alpha 1-adrenergic antagonism in humans. J Cardiovasc Pharmacol. 1985;7 (Suppl 7):S123–S125. doi: 10.1097/00005344-198500077-00036. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES